Aptitude and Google jointly published machine learning-guided aptamer research on Nature Communications
Aptitude received California CLIA license for high-complexity molecular testing
Aptitude was admitted into the prestigious NIH RADx program
Imagine a synthetic antibody that:
is highly stable, resistant to denaturing, and works on diverse platforms
binds with high affinity and specificity to intractable targets, and discriminates targets that differ by only a single functional group
accommodates site-specific modification by various functional groups, and unlocks a multitude of unique applications
Imagine a company who can turn that dream into reality.
Welcome to the reality of Aptitude.
Find out who is behind the Aptitude technology